Inactive Instrument

BLACKMORES

Equities

BKL

AU000000BKL7

Blackmores Limited Resolves Not to Pay an Interim Dividend for the First-Half Period Ended 31 December 2019

February 24, 2020 at 04:39 pm EST

On 11 February 2020, Directors of Blackmores Limited resolved not to pay an interim dividend in respect of the first-half period ended 31 December 2019. This decision was announced on 12 February 2020.

Latest news about BLACKMORES

Kirin Health Science Australia Pty Ltd completed the acquisition of Blackmores Limited from AustralianSuper Pty Ltd., FIL Limited, Marcus Charles Blackmore and others.	23-08-09	CI
Blackmores Limited(ASX:BKL) dropped from S&P Global BMI Index	23-07-24	CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX 200 Index	23-07-24	CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX 300 Index	23-07-24	CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX All Ordinaries Index	23-07-24	CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX 200 Consumer Staples Sector Index	23-07-24	CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX Small Ordinaries Index	23-07-24	CI
At-home health test maker Thorne explores sale -sources	23-07-21	RE
At-home health test maker Thorne explores sale-sources	23-07-21	RE
Blackmores Acquisition by Kirin Holdings Takes Legal Effect	23-07-21	MT
Blackmores Limited Announces Fully Franked Special Dividend, Payable on 1 August 2023	23-07-12	CI
Japan's Astellas to buy Iveric Bio for $5.9 bln to expand eyesight treatments	23-04-30	RE
Japan stocks extend losses as Nomura, Advantest slump after weak results	23-04-26	RE
Blackmores Shares Jump 21% on Kirin's A$1.84 Billion Takeover Proposal	23-04-26	DJ
Australia shares slip as financials drop on recession fears	23-04-26	RE
Japan's Kirin Holdings to acquire Australia's Blackmores for $1.27 billion	23-04-26	RE
Kirin Holdings Company, Limited entered into scheme implementation deed to acquire Blackmores Limited for AUD 1.9 billion.	23-04-26	CI
Blackmores Recommends A$1.84 Billion Takeover Proposal by Kirin	23-04-26	DJ
Blackmores' Net Profit Jumps 20% in Fiscal H1	23-02-23	MT
Blackmores Seeks Acquisitions	23-02-22	CI
Transcript : Blackmores Limited, H1 2023 Earnings Call, Feb 23, 2023	23-02-22
Blackmores Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on March 28, 2023	23-02-22	CI
Blackmores Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Blackmores Ceases 1,447 Conditional Rights	23-01-11	MT
Bloomberg Video: Blackmores CEO on China Market, New Opportunities	22-11-29	MT

Chart BLACKMORES

Duration

Period

More charts

Company Profile

Blackmores Limited is an Australia-based natural healthcare company. The Company's principal activity is the development, manufacture, sales, and marketing of health products for humans and animals, including vitamins and herbal and mineral nutritional supplements. Its segments include Australia and New Zealand (ANZ), China, and International. The ANZ segment consists of Blackmores, PAW by Blackmores, Impromy and BioCeuticals practitioner brands sold across Australia and New Zealand, and manufacturing on behalf of third parties within its Braeside facility. The China segment consists of Blackmores brand in China through CBEC (in country), China Export Division, Hong Kong and Taiwan. The International segment consists of Blackmores brands in Thailand, Malaysia, Singapore, South Korea, Indonesia, India, Philippines, Vietnam, and Pakistan. The Company's evidence-based range of brands includes Blackmores, a natural health brand; BioCeuticals, and PAW, a natural health product for pets.

Sector

More about the company